The Plus+Ultra Science & Wellness Journal
Evidence-backed guides on sleep architecture, metabolic health, cellular longevity, and daily supplement protocols.
Natural GLP-1 Support vs. Ozempic: What’s Actually Different
How prescription GLP-1 drugs and natural GLP-1 support differ, mechanism by mechanism, so you can decide what makes sense for your own approach.
Read Article →
The GLP-1 Revolution: What Ozempic Started
What GLP-1 is, where your body makes it, and why a hormone from the gut became the center of the conversation about appetite and...
Read Article →
What Is the Best Magnesium to Take With Tirzepatide or Semaglutide?
Quick Answer: People on tirzepatide (Mounjaro/Zepbound) or semaglutide (Ozempic/Wegovy) face increased magnesium risk due to reduced food intake, GI-related mineral losses, and metabolic changes....
Read Article →
Retatrutide vs Tirzepatide vs Semaglutide: How the Three GLP Drugs Compare
Quick Answer: Semaglutide (Wegovy/Ozempic) activates GLP-1 receptors only and produced ~15% mean body weight loss in STEP trials. Tirzepatide (Zepbound/Mounjaro) adds GIP receptor agonism...
Read Article →
Retatrutide Side Effects: What the Clinical Data Shows and What Remains Unknown
Quick Answer: In Phase 2 clinical trials, retatrutide's most common side effects were gastrointestinal — nausea, vomiting, and diarrhea — occurring in approximately 50%...
Read Article →
What Is Tirzepatide? How Mounjaro and Zepbound Work, Explained
Quick Answer: Tirzepatide is a weekly injectable medication developed by Eli Lilly that activates two gut hormone receptors — GIP and GLP-1 — to...
Read Article →
Tirzepatide vs Semaglutide: The Dual vs Single Agonist Comparison
Quick Answer: Tirzepatide (Mounjaro/Zepbound) targets two receptors — GIP and GLP-1 — while semaglutide (Ozempic/Wegovy) targets GLP-1 alone. In clinical trials, tirzepatide produced greater...
Read Article →
Semaglutide Side Effects: What the Clinical Data Actually Shows
Quick Answer: The most common semaglutide side effects are gastrointestinal — nausea affects roughly 44% of patients, diarrhea 30%, and vomiting 24%, based on...
Read Article →
Retatrutide: What the Phase 3 Clinical Trials Actually Showed
Quick Answer: Retatrutide is a triple agonist drug in development by Eli Lilly that activates GIP, GLP-1, and glucagon receptors simultaneously. In Phase 2...
Read Article →
